ProPhase Labs, Inc. Debt Securities, Available-for-sale, Amortized Cost
ProPhase Labs, Inc. (PRPH) had Debt Securities, Available-for-sale, Amortized Cost of $148.00 thousand as of 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-06-01
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $148.00K.
- 2024-12-31: Debt Securities, Available-for-sale, Amortized Cost $3.53M; Debt Securities, Available-for-sale, Amortized Cost as first filed $148.00K.
- 2023-12-31: Debt Securities, Available-for-sale, Amortized Cost $3.53M.
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost $7.19M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2025-12-31 | $148.00K 10-K · filed 2026-06-01 | |
| 2024-12-31 | $3.53M 10-K · filed 2026-06-01 | $148.00K 10-K · filed 2025-04-01 |
| 2023-12-31 | $3.53M 10-K · filed 2025-04-01 | |
| 2022-12-31 | $7.19M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $3.79M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $3.60M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $3.51M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $8.95M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $14.24M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $18.18M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $3.55M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $1.65M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $1.41M 10-Q · filed 2020-11-19 | |
| 2020-06-30 | $3.33M 10-Q · filed 2020-08-11 | |
| 2019-12-31 | $928.00K 10-K · filed 2021-03-31 | |
| 2019-09-30 | $3.77M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $4.69M 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $4.24M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $6.71M 10-K · filed 2020-03-26 | |
| 2018-09-30 | $6.89M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $6.83M 10-Q · filed 2018-08-20 | |
| 2018-03-31 | $18.45M 10-Q/A · filed 2018-08-20 | |
| 2017-12-31 | $18.84M 10-K · filed 2019-03-26 | $18.69M 10-K · filed 2018-03-28 |
| 2017-09-30 | $23.68M 10-Q/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |